CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
Case Report: Pembrolizumab Monotherapy Achieves Durable Disease Control in a Patient with BRAF V600E-Mutant Advanced Lung Adenocarcinoma and High PD-L1 Expression Intolerant to BRAF/MEK Inhibition
Provisionally accepted
- First People's Hospital of Changzhou, Changzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: To investigate the follow-up treatment options and prognosis in patient with non-small cell lung cancer (NSCLC) harboring a BRAF V600E mutation who is intolerant to targeted therapy. Case presentation: A patient with a 30-year smoking history and well-controlled hypertension developed lung adenocarcinoma (left upper lobe; T2aN2MO, Stage IIIA; Karnofsky Performance Status: 90) after radical lung cancer surgery. The patient was later hospitalized for "recurrent hemoptysis" and received pemetrexed adjuvant chemotherapy combined with cisplatin. The patient, subsequently developed focal brain metastasis for which he received radiotherapy. However, the patient experienced recurrent pulmonary lesions. The genetic testing and immunohistochemistry analysis revealed the presence of a BRAF V600E mutation and high PD-L1 expression. Consequently, a targeted therapy regimen combining low to moderate doses of dabrafenib and trametinib was initiated. However, the patient developed severe and rare adverse reactions, prompting a switch to pembrolizumab monotherapy. Outcomes: The patient exhibited significant symptomatic improvement, with a marked reduction in recurrent and metastatic lesions. Subsequent follow-up assessments indicated stable disease with no evidence of progression. Moreover, only one low-grade immune-related adverse event was observed during the course of immunotherapy. Conclusion: Patients with advanced NSCLC and BRAF mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.
Keywords: BRAF V600E mutation, case report, Immunecheckpoint inhibitor, Non-small cell lung cancer, PD-L1
Received: 08 Oct 2025; Accepted: 26 Jan 2026.
Copyright: © 2026 Zhao, zhou and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wei Zhao
Chunlai Feng
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.